Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
The funds raised will be used to advance Elkedonia's novel neuroplastogen approach to identify and optimize drug-like small molecule inhibitors of Elk1, a novel intracellular target previously considered to be "undruggable". Elk1 plays a pivotal role in reward brain circuits and neuroplasticity. These mechanisms are often altered in conditions like depression, Post-Traumatic Stress Disorder (PTSD), and addiction, making them chronic instead of transient. Preclinical and clinical studies suggest that Elk1 inhibition offers a promising and differentiated new approach to treating treatment-resistant depression, with rapid efficacy and without the side effects of psychedelics or ketamine derivatives, such as sedation, dependence, or hallucinations. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy.
This scientific and commercial potential was identified early by Argobio, which selected and developed Elkedonia within its venture studio. Founded in Paris and backed by leading investors including Angelini Ventures, Argobio partners with European academic institutions to transform early-stage discoveries into biotech companies, with a focus on rare diseases, neuroscience, oncology and immunology.Elkedonia is the first of these ventures to reach a significant financing milestone — a clear validation of Argobio's model and approach. This strong European investor syndicate reflects both the confidence of Argobio's founding investors in its model and Elkedonia's ability to attract leading life sciences investors at the seed stage. Building on this momentum, Argobio continues to expand its portfolio with the ambition to scale a repeatable model of biotech creation, driven by scientific excellence, entrepreneurial leadership and long-term investor alignment.
'We are excited to support Elkedonia's groundbreaking work in advancing neuroplastogens, which represents a potential first-in-class approach to treating depression,' said Fabrizio Calisti, Medical Director at Angelini Ventures. 'The novel nature of Elkedonia's target Elk1, previously thought to be undruggable, sets the company apart in the landscape of depression treatments, and we are proud to be part of this transformative journey. This investment reflects Angelini Ventures' commitment to supporting the exciting science coming out of European academic laboratories at the earliest stages via Argobio and subsequently providing further capital through our venture fund to accelerate the translation of cutting-edge research into therapies with the potential to transform outcomes for people with neuropsychiatric disorders.'
Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Elkedonia's Board of Directors.
'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.'
***
Notes to EditorsAbout Angelini Ventures
Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies.
To date, Angelini Ventures has invested around €100 million into 21 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. www.angeliniventures.com
About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates.www.angeliniindustries.com
About Elkedonia Elkedonia is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD).www.elkedonia.com
About ArgobioArgobio is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.www.argobiostudio.com
ContactsAngelini VenturesMartina Palmese, Communications Coordinatormartina.palmese@angeliniventures.com
Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, daniele.pinosa@secnewgate.it; Tel. +39 3357233872Fausta Tagliarini; fausta.tagliarini@secnewgate.it; Tel. +39 3476474513Daniele Murgia; daniele.murgia@secnewgate.it; Tel. +39 3384330031
Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@medistrava.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
How to find the cheapest train tickets as passengers face 5.5% rise in rail fares
Campaigners have said a potential 5.5% rise in regulated fares is 'outrageous' - but there are some ways you can save money when buying tickets. Train fares in England could jump by 5.5% next year following an uptick in UK inflation, financial analysts have warned. July's Retail Prices Index (RPI) measure of inflation - which is often used to determine increases in the cost of train tickets - will be announced on Wednesday. While the government has not confirmed how it will determine the cap in regulated fare rises for 2026, this year's hike of 4.6% was one percentage point above the RPI rate in July last year. With this July's RPI figure expected to be 4.5%, according to banking group Investec, train fares in England could jump by 5.5%. Bruce Williamson, spokesman for transport pressure group Railfuture said "it would be outrageous" if fares rose by that much, adding that there is no justification in "jacking up fares above inflation". "It's ripping off the customer, driving people off the trains and onto our congested road network, which is in no-one's interest." Chief executive of lobby group Campaign for Better Transport, Ben Plowden, warned that rising fares are "putting people off rail travel", pointing to a survey that found 71% of people would be more likely to take the train if prices were lower. With passengers facing yet another rise in fares, here is a guide on how to save as much money as possible on your train tickets. Get a Railcard There are currently nine available Railcards, depending on your situation and needs, which can knock off 1/3 of your train fare. Most Railcards can be purchased online with the option to download as a digital Railcard to your smartphone or device with our Railcard App. Some one-year Railcards can also be purchased at any staffed National Rail ticket office. You can book your discounted train tickets online or in person, but you must be able to present your Railcard to inspectors during your journey for your ticket to be valid. 16-17 Saver: £35 for one year 16-25 Railcard: £35 for one year, £80 for three years 26-30 Railcard: £35 for one year Disabled Persons Railcard: £20 for one year, £54 for three years Family & Friends Railcard: £35 for one year, £80 for three years Network Railcard: £35 for one year Senior Railcard: £35 for one year, £80 for three years Two Together Railcard: £35 for one year Veterans Railcard: £35 for one year, £80 for three years Book in advance Train companies sell around a million advance tickets every week, according to National Rail. Tickets are usually released 12 weeks in advance, although this can vary, the rail industry body says, adding that the "earlier you book, the better the chance you have of getting the best price". Advance tickets are still available until the day of travel on many routes - sometimes up to 10 minutes before departure. While advance fares are single tickets valid only on the date and train shown on the ticket, they can be combined with other tickets to create an entire journey. Changes can be made before departure, but may be subject to a £10 admin fee and other terms and conditions. Buy a season ticket If you make the same journey more than once a week, it might be worth investing in a season ticket rather than buying tickets daily. An annual season ticket offers a full year's worth of travel for the price of 10 months and 12 days, Network Rail says. Part-time commuters may also want to consider Flexi season tickets, which give passengers day return travel for eight days within a 28-day period. Passengers don't need to choose their travel days in advance, providing plenty of flexibility for hybrid workers who only occasionally come into the office. Depending on your circumstances, you might save more money with either a weekly, monthly or annual season ticket. You can use National Rail's season ticket calculator here to see which ticket is right for you. Travel in a group If you're a small group travelling together, you can also use GroupSave on a variety of Off-Peak tickets across the rail network. GroupSave tickets save up to 1/3 on rail fares for adults travelling in a group of three to nine people. They can be bought for single or return journeys at off-peak or super-off peak times. Make sure you stick with the whole group you booked for to ensure your tickets remain valid during your journey. Travel during quieter times Off-Peak fares are cheaper tickets for travelling at less busy times during weekdays, and all day on weekends, National Rail says. You may have to travel at specified times, or on specified days or routes. On longer distance journeys, if you travel in a peak period one way but want to return when it is less busy, consider booking a combination of advance, off-peak and anytime fares to get the best deal. Rover and Ranger tickets Most train companies offer a selection of Rover tickets and Ranger tickets, which offer unlimited travel within a specified area and time period. Ranger tickets are valid for one day only, while Rover tickets are valid for longer (although still within a limited time period). For example, you could buy a Rover ticket that allows travel within a specific geographical area for three consecutive days, or within a 15-day period. These tickets may also include local bus travel, and there are often other offers and discounts available, including 50% off for children aged five to 15, 50% off for people with a 16-17 Saver Railcard and 1/3 off fares with other Railcards. How are train fares decided? About 45% of fares on Britain's railways are regulated by the Westminster, Scottish and Welsh governments, while the rest are set by train operators themselves. Regulated fares include season tickets on most commuter journeys, some off-peak return tickets on long-distance routes, and flexible tickets for travel around major cities. The Department for Transport (DfT) said there will be an update on changes to regulated fares later this year. Operators set rises in unregulated fares, although these are likely to be very close to regulated ticket increases because their decisions are heavily influenced by governments. A DfT spokesperson said: "The Transport Secretary has made clear her number one priority is getting the railways back to a place where people can rely on them. "The government is putting passengers at the heart of its plans for public ownership and Great British Railways, delivering the services they deserve and driving growth. "No decisions have been made on next year's rail fares but our aim is that prices balance affordability for both passengers and taxpayers." Read more Everything you need to know as ScotRail prepares to scrap peak train fares (The National) Voices: 'We're falling behind': Heathrow expansion sparks backlash over UK's 'outdated' travel infrastructure (The Independent) Train firms accused of 'vexatious' plot to derail Labour nationalisation (The Telegraph)
Yahoo
10 minutes ago
- Yahoo
James Pearce confirms Liverpool forward WILL stay after remarkable U-turn
Liverpool's attack has undergone a profound transformation over the course of this transfer window. The club's sporting director Richard Hughes has spent big money on Florian Wirtz and Hugo Ekitike while also overseeing outgoing deals for Darwin Nunez and Luis Diaz. 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the away range TODAY LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! There could be more action in the window with Alexander Isak still being eyed by the Reds' top brass. Also, players like Ben Doak and Harvey Elliott could be shown the exit as Hughes and Arne Slot seek to recoup as much money as they can in sales. 🔴 Shop the LFC 2025/26 adidas away range One other player tipped to depart this summer has been Federico Chiesa. The Italian international can call himself a Premier League champion having played his part in last season's title win but overall it was a disappointing campaign on a personal level. Liverpool change their minds over forward deal Chiesa was injured when he signed from Juventus - and he never really found his groove. According it's been speculated that he would return to Serie A and there have been several teams linked with Atalanta, AC Milan and Napoli among those most frequently mentioned. But now it appears that the 27-year-old has earned himself a second chance under head coach Arne Slot. No serious bids for Chiesa Chiesa's fate looked sealed when he was left out of the touring party for the preseason tour in Asia. But he was included on the bench for the season opener against Bournemouth. And with Liverpool requiring a goal, Slot turned to the Italian. He duly delivered - with Chiesa's first-ever Premier League strike putting the Reds 3-2 up late in the game at Anfield. His cameo has led to talk over what might happen before the end of the transfer window. And while Italian sources have always been consistent in their belief that either Milan or Napoli would strike, it's been confirmed by the Athletic's James Pearce that Liverpool are STILL awaiting a substantial bid for Chiesa. © IMAGO - Federico Chiesa Liverpool 'The expectation was that Chiesa would also move on, but for all the rumours about a possible return to Italy, Liverpool haven't received one serious offer,' the report reads. 'Given the ongoing uncertainty surrounding the club's pursuit of Newcastle United's Alexander Isak, Liverpool should be keeping hold of Chiesa as cover. 'Offloading him at this stage of the window would make little sense. He should be given the opportunity to build on this.' Chiesa might now go on and prove himself to be a useful rotation option as well as an understudy for Mo Salah. It's taken Chiesa a while to reach this point but Friday night perhaps suggested he had finally arrived. Either Italian suitors are going to have to stump up the requisite fee and wages or else it's increasingly likely Chiesa will be staying after all against the odds.
Yahoo
10 minutes ago
- Yahoo
Report – Inter Milan Slap €20M Price Tag On Galatasaray, Lille & Neom Target
Inter Milan have reportedly slapped a price tag of €20 million on Galatasaray, Lille, and Neom target Benjamin Pavard. This according to today's print edition of Rome-based newspaper Corriere dello Sport, via FCInterNews. Recent reports have suggested that Inter are ready to sell Benjamin Pavard. The likes of Galatasaray, Lille, and Saudi Pro League side Neom have all shown an interest. Inter signed Pavard two years ago from Bayern Munich. And the France international has certainly had his part to play, helping the Nerazzurri to the Serie A title in his first season at the club. But perhaps Pavard, who turns thirty next season, is not in line with the future of Inter's project. Inter Milan Want €20M For Galatasaray, Lille & Neom Target Benjamin Pavard SEATTLE, WASHINGTON – JUNE 20: Benjamin Pavard of FC Internazionale Milano faces the media during the Training/Press Conference ahead of their FIFA Club World Cup 2025 match between FC Internazionale Milano and Urawa Red Diamonds at Virginia Mason Athletic Center on June 20, 2025 in Seattle, Washington. (Photo by) The key question would be what kind of fee Inter would want for Pavard. The Nerazzurri signed the Frenchman from Bayern Munich in 2023. They paid a fee of around €35 million to bring him in. According to the Corriere dello Sport, though, Inter would be willing to sell Pavard for considerably less than that. The Nerazzurri would not, however, be willing to take a capital loss on the 29-year-old defender. Therefore, the Corriere report, Inter's asking price is right around €20 million.
